Cover image of the article: Comparison of Outcome in Radioiodine Induced Euthyroid and Hypothyroid Patients

Image Credit:Int J Endocrinol Metab

Comparison of Outcome in Radioiodine Induced Euthyroid and Hypothyroid Patients

Authors

F Shekholeslami1, L Ataie1, M Hedayati1, Y Mehrabi1, F Azizi2,*
1Endocrine Research Center and the Division of Cardiology, Taleghani Medical Center, Shaheed Beheshti University of Medical Sciences, IR.Iran
2Endocrine Research Center and the Division of Cardiology, Taleghani Medical Center, Shaheed Beheshti University of Medical Sciences, Azizi@erc.ac.ir, IR.Iran
*Corresponding Author: Endocrine Research Center and the Division of Cardiology, Taleghani Medical Center, Shaheed Beheshti University of Medical Sciences, Azizi@erc.ac.ir, IR.Iran. Email: Azizi@erc.ac.ir

International Journal of Endocrinology and Metabolism:Vol. 3, issue 4
Published online:Oct 31, 2005
Article type:Research Article
Received:Jan 01, 2005
Accepted:Nov 01, 2005
How to Cite:Shekholeslami F, Ataie L, Hedayati M, Mehrabi Y, Azizi F. Comparison of Outcome in Radioiodine Induced Euthyroid and Hypothyroid Patients. Int J Endocrinol Metab. 2005;3(4):. doi:

Abstract

The major consequence of radioiodine therapy for thyrotoxicosis is hypothyroidism and long-term precise management of hypothyroidism may be problematic. In this study, the long-term outcomes were compared in radioiodine treated euthyroid and hypothyroid patients on thyroid hormone treatment. Materials and Methods: One hundred and thirty eight patients with diffuse toxic goiter were treated with radioactive iodine. One hundred and seven patients (78%) returned for follow up visits for up to 11.5±0.8 years. Numbers of occurrences of thyroid dysfunction in each patient were recorded and a total cost of management was calculated. Results: At the end, 41 patients (38%) were still euthyroid (group 1) and 66 (62%) became hypothyroid (group 2). Serum, FT4, FT3, TSH, thyroid antibodies, lipid profile, calcium, phosphorus, and PTH were measured and bone mineral density, ECG and echocardiography were performed. There was no significant difference in age, sex, duration of symptoms and thyroid function between the 2 groups. The cost of treatment was lower in group 1 than in group 2. During 11.5 years of follow up, percentage of elevated and suppressed TSH in groups 1 and 2 were 0.02 and 20.5, p<0.001 and 7.9 and 13.4, p<0.001, respectively. At the end of 10 years, goiter rate, serum T4, T3, thyroid antibodies, lipids, Ca, P and PTH and bone mineral density and echocardiography data were not signifanctly different between two groups. However, mean serum TSH and number of TSH above 5 mU/L was greater in roup 2 than 1 (p<0.01). Conclusion: It is concluded that thyroid derangements frequently occur in patients who become hypothyroid after radioiodine therapy, while on replacement therapy.

Highlights

Full Text

Full text is available in PDF

Copyright

© 2005, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Similar Articles

31
Jan
2026
Sustained Control of Hyperthyroidism in Graves’ Disease: Comparison of Thyroidectomy and Long-Term Antithyroid Treatment

Sustained Control of Hyperthyroidism in Graves’ Disease: Comparison of Thyroidectomy and Long-Term Antithyroid Treatment

Hengameh Abdi,
Miralireza Takyar,
Ladan Mehran,
Safdar Masoumi,
Atieh Amouzegar,
Fereidoun Azizi

Abdi H, Takyar M, Mehran L, Masoumi S, Amouzegar A, et al. Sustained Control of Hyperthyroidism in Graves’ Disease: Comparison of Thyroidectomy and Long-Term Antithyroid Treatment. Int J Endocrinol Metab. 2026;24(1):e164940. doi: https://doi.org/10.5812/ijem-164940

12
Oct
2019
Systemic Thyroid Hormone Status in Treated Graves’ Disease

Systemic Thyroid Hormone Status in Treated Graves’ Disease

Fereidoun Azizi,
Atieh Amouzegar,
Maryam Tohidi,
Mehdi Hedayati,
Leila Cheraghi,
Yadollah Mehrabi

Azizi F, Amouzegar A, Tohidi M, Hedayati M, Cheraghi L, et al. Systemic Thyroid Hormone Status in Treated Graves’ Disease. Int J Endocrinol Metab. 2019;17(4):e95385. doi: https://doi.org/10.5812/ijem.95385

31
Jan
2008
Randomized Controlled Trial on Comparison of the Course of Hyperthyroid Patients with and Without Antithyroid Drugs During the Immediate Post Radioactive Iodine Treatment Period

Randomized Controlled Trial on Comparison of the Course of Hyperthyroid Patients with and Without Antithyroid Drugs During the Immediate Post Radioactive Iodine Treatment Period

MFR Gafate,
L Mercado-Asis

Gafate M, Mercado-Asis L. Randomized Controlled Trial on Comparison of the Course of Hyperthyroid Patients with and Without Antithyroid Drugs During the Immediate Post Radioactive Iodine Treatment Period. Int J Endocrinol Metab. 2008;6(1):. doi:

29
Sep
2012
Recombinant TSH and Lithium Overcomes Amiodarone-Induced Low Radioiodine Uptake in a Thyrotoxic Female

Recombinant TSH and Lithium Overcomes Amiodarone-Induced Low Radioiodine Uptake in a Thyrotoxic Female

Nestor Eric R. Laplano,
Leilani B. Mercado-Asis

Laplano NER, Mercado-Asis LB. Recombinant TSH and Lithium Overcomes Amiodarone-Induced Low Radioiodine Uptake in a Thyrotoxic Female. Int J Endocrinol Metab. 2012;10(4):. doi: https://doi.org/10.5812/ijem.5406

More by these authors

F ShekholeslamiPubMedScholar
M HedayatiPubMedScholar
Y MehrabiPubMedScholar
Share
Cited by
Metrics